Our approach to product development starts by identifying areas of high unmet medical need for which genomic information could significantly improve disease staging and/or patient management decisions. We look for opportunities where current staging does not sufficiently identify patient risk or where it would be clinically useful to understand the likely response of a tumor to the standard of care. We dig deep into skin cancer clinical treatment pathways to find areas of unmet medical need where we can leverage our expertise in cancer genomics and the use of artificial intelligence techniques to improve – and potentially transform – patient outcomes. Operating under CAP-accredited, CLIA-certified laboratory conditions, we focus on developing clinically impactful diagnostic, prognostic, and predictive tests discovered in-house or in-licensed from third party institutions.

Pioneering Developments in Molecular Diagnostics

Our research and development efforts harness the capabilities of artificial intelligence to apply deep learning using neural networks and other techniques to build and refine proprietary algorithms. The goal is to identify critical molecular characteristics that provide important diagnostic information about an individual patient’s tumor. We then partner with academic researchers to complete multi-center clinical studies that are designed to validate a test’s accuracy. Following clinical validation, we rapidly institute clinical utility studies to document and ensure appropriate use.

Using these techniques, we’ve successfully developed and commercialized innovative tests that are helping patients with melanoma, cutaneous squamous cell carcinoma, and uveal melanoma. As we continue our active research and development programs, our goal is to bring even more innovation to the management of patients with skin cancers and other dermatology disorders.